Traduction de «authorities have been » (Néerlandais → Français) :

Nevertheless, in view of the fact that this type of drink is already allowed in several European countries and taking into account the European regulations concerning this type of product, in the end, the competent French authorities have been obliged to give their approval (Decree of the European Court of Justice, Press release No. 12/04, 2004) for this beverage, which was marketed on 15 July 2008.
Néanmoins, considérant que ce type de boisson est déjà autorisé dans plusieurs pays d’européens et compte tenu de la réglementation européenne sur ce type de produit, les autorités compétentes françaises ont finalement dû l’autoriser (Arrêt de la Cour de Justice européenne, Communiqué de presse n° 12/04, 2004). Sa commercialisation a effectivement débuté en date du 15 juillet 2008.

Accordingly, what follows is not meant as an exhaustive inventory of all the initiatives that have already been taken at all the levels of authority, but as a grouping together of various examples of initiatives taken in this field, based on the most important courses of action.
La présentation qui suit ne vise donc pas à dresser un inventaire exhaustif de toutes les initiatives déjà prises à tous les niveaux de pouvoir mais bien de regrouper à partir des axes d’actions principaux divers exemples d’initiatives prises dans le domaine.

The different projects that have been developed are either based on private initiatives or organised and subsidised on a local level (local authorities, province…).
Les différents projets développés le sont soit sur base d’initiatives privées, soit subsidiées et mises en place à un niveau local (communes, province…).

The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.
The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.

The data in this source need, of course, to agree with those that have been approved or determined by the competent authority for marketing authorisation – MA (FAMHP), price (FPS Economy) and reimbursement modalities (RIZIV-INAMI), respectively.
The data in this source need, of course, to agree with those that have been approved or determined by the competent authority for marketing authorisation – MA (FAMHP), price (FPS Economy) and reimbursement modalities (RIZIV-INAMI), respectively.

Using cell-culture technology, first batches have been successfully produced for both the wild virus strain and the “reassortant seed” modified virus recommended by the WHO and health authorities.
Utilisant la technologie de la culture cellulaire, les premiers lots ont été fabriqués avec succès à la fois contre la souche dite sauvage ainsi que contre le virus réassorti (modifié génétiquement) selon les recommandations de l’OMS et des autorités sanitaires.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.